Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine ER for Bladder Wall Thickness in OAB
NCT00137397Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2004
- Countries
- 1
- Sponsor
- Viatris
- Modality
- Small Molecules
- Drugs
- tolterodine
- Conditions
- overactive bladder (OAB)
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Tolterodine ER with Placebo (2 arms). Primary endpoint: Change in Bladder Wall Thickness at 12 weeks. Started Nov 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Tolterodine ER
Tolterodine ER
Placebo
Placebo
03
Who it enrols
Female patients with symptoms of overactive bladder for more than 6 months and bladder wall thickness of 5mm or more. Patients with significant stress incontinence, history of recurrent UTIs, or recent treatment with OAB drugs are excluded.
04
Endpoints
Primary
Change in Bladder Wall Thickness
Secondary
Change in Bladder Wall Thickness
Beyond the preview
Go deeper on NCT00137397.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137397.